Today we shared our financial results and operational activities for the second quarter and first half of 2024. In transitioning from Sosei Heptares to Nxera Pharma, we are united under a single identity with a clear purpose to become a leading technology driven biopharmaceutical company bringing new medicines to patients in Japan and globally. Read the full announcement here: https://lnkd.in/e65D3HGB #FinancialResults
Nxera Pharma
バイオテクノロジー研究
Tokyo、Tokyo9,174人のフォロワー
Nxera Pharma is a technology powered biopharma company.
概要
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery “NxWave” platform to provide a sustainable source of best- or first-in-class candidates. Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
- ウェブサイト
-
https://www.nxera.life
Nxera Pharmaの外部リンク
- 業種
- バイオテクノロジー研究
- 会社規模
- 社員 201-500名
- 本社
- Tokyo、Tokyo
- 種類
- 上場企業
- 創立
- 1990
- 専門分野
- GPCR、Drug Discovery、Pre-Clinical、Immunology、Gastroenterology、Neurology、Inflammatory、Chemistry、Molecular Pharmacology、Development、Computational Chemistry、Structure-Based Drug Design platform capabilities、Novel Medicines
場所
Nxera Pharmaの社員
-
Sital Kotecha
Global Head of IT - Business Applications & Corporate Systems
-
Gerard Collins
Human Resources Director at Sosei Heptares
-
Chris de Graaf
Senior Director, Head of Computational Chemistry - Sosei Heptares
-
Marcus Messenger
Senior Vice President, Head of Business Development at Nxera Pharma
アップデート
-
Our CEO, Chris Cargill, attended the Drug Discovery Ecosystem Summit earlier this week which was held at Prime Minister Fumio Kishida's office in Tokyo. It was a great opportunity to directly address key members of the Japanese government and healthcare agencies on crucial ideas to stimulate the drug discovery ecosystem in Japan. We commend the Kishida government’s commitment to this important initiative. https://lnkd.in/g_PMy99e
-
-
Today is National Schizophrenia Awareness Day. Schizophrenia is a mental illness that affects millions of individuals worldwide. Neurological diseases and neuropsychiatric disorders such as schizophrenia are a key area of focus for Nxera. We are developing a number of potential treatments for schizophrenia that aim to improve outcomes and address the high unmet patient need. Read more about our pipeline here: https://lnkd.in/gq3d8arw Learn more about National Schizophrenia Awareness Day here: https://lnkd.in/gaEA7skn #SchizophreniaAwarenessDay #schizophrenia #GPR52 #Muscarinic
🚨 It's National Schizophrenia Awareness Day! Despite 1 in 100 people living with the condition, it is still severely stigmatised and misunderstood. Share this post so that people get the facts 👇 #NSAD24
-
Our busy summer hosting work experience students is underway! The students will spend time across various departments to gain experience and learn more about the different areas of the business. From learning how to use computational chemistry for drug discovery, to understanding the role of legal and intellectual property, we hope to demonstrate the breadth of opportunities available in biotech and inspire the students for their future careers. Learn more: https://www.nxera.life/
-
-
We are pleased to announce that we have reached an important R&D milestone under our multi-target discovery collaboration with AbbVie targeting neurological diseases. This achievement is testament to the expertise and diligence of our platform technology team to deliver multiple stabilized GPCRs (NxStaRs) to support further structure-based drug design. Our history of collaborating with AbbVie demonstrates our highly productive working relationship and complementary capabilities, and we look forward to continuing the next stages of this project. Full PR Link: https://bit.ly/4cdDr3M #neurology #GPCR #SBDD #drugdesign
-
-
Celebrating acceptance, diversity and inclusivity at Nxera Pharma, where everyone is welcome to be their true authentic self 🌈 #PrideMonth #Authenticity #Diversity #Inclusivity #LGBTQIA
-
-
Nxera Pharmaさんが再投稿しました
Exciting updates from #BIO2024! 🌟 Tune in to this special episode of the #BioCenturyThisWeek podcast featuring Chris Cargill, CEO of Nxera Pharma, discussing the growing APAC presence at BIO 2024, Japan's biotech ecosystem, and how Nxera's strategy helps innovative medicines to reach patients in Japan. Plus, get insights from Steve Usdin on the House's Biosecure decision and Karen Tkach Tuzman's panel on radiopharmaceuticals. Tune in on your favorite podcast platform: https://lnkd.in/gcbtZrvR Special thanks to Nxera Pharma for sponsoring this episode. #BiosecureAct #Biotech #Biopharma #radiopharmaceuticals
-
-
Our CEO, Chris Cargill, was a guest speaker on the latest BioCentury This Week podcast. Chris spoke to Jeff Cranmer and the team about the increased APAC presence at this year’s BIO conference, the evolving biotech ecosystem in Japan and how Nxera’s strategy allows innovative medicines to reach patients in Japan. Listen to the podcast here: https://lnkd.in/eC6P4wam BioCentury Inc.
-
-
We are pleased to share that we will receive $4.6 million in milestone payments from Centessa Pharmaceuticals following progress of Centessa’s novel orexin receptor 2 (OX2R) agonist, ORX750. The milestone was achieved with clearance of the ORX750 IND application and progression of ORX750 into a Phase 1 clinical trial. Read the full announcement here: https://lnkd.in/gN4E3erz
-
We have expanded our strategic R&D partnership with PrecisionLife into auto-immune disorders to identify novel targets for drug discovery. The partnership aims to establish new drug targets and subsequently potential precision targeted therapies for auto-immune disorders, each linked to subgroups of patients by PrecisionLife’s mechanism-based patient stratification biomarkers. Read more here: https://lnkd.in/eTuVbRxr
-